RESUMEN
Exhaled gas analysis is a non-invasive test ideal for continuous monitoring of biological metabolic information. We analyzed the exhaled gas of patients with inflammatory diseases for trace gas components that could serve as biomarkers that enable early detection of inflammatory diseases and assessment of treatment efficacy. Furthermore, we examined the clinical potential of this method. We enrolled 34 patients with inflammatory disease and 69 healthy participants. Volatile components from exhaled gas were collected and analyzed by a gas chromatography-mass spectrometry system, and the data were examined for gender, age, inflammatory markers, and changes in markers before and after treatment. The data were tested for statistical significance through discriminant analysis by Volcano plot, Analysis of variance test, principal component analysis, and cluster analysis comparing healthy and patient groups. There were no significant differences in the trace components of exhaled gas by gender or age. However, we found differences in some components of the exhaled gas between healthy and untreated patients. In addition, after treatment, gas patterns including the patient-specific components changed to a state closer to the inflammation-free status. We identified trace components in the exhaled gas of patients with inflammatory diseases and found that some of these regressed after treatment.
Asunto(s)
Compuestos Orgánicos Volátiles , Humanos , Cromatografía de Gases y Espectrometría de Masas/métodos , Compuestos Orgánicos Volátiles/análisis , Pruebas Respiratorias/métodos , Biomarcadores/análisis , EspiraciónRESUMEN
The present article, dedicated to Dr NS Dhalla on the occasion of the jubilee of his life's work, is a brief review of articles based on the authors' studies of sarpogrelate conducted in collaboration with Dr NS Dhalla. These studies on the effects of sarpogrelate on cardiovascular disorders have been ongoing for more than 10 years, and 10 articles have been published to date.
RESUMEN
BACKGROUND: A device developed based on ink-jet printer technology can precisely control the size and volume of droplets ejected. Here, we evaluated the application of this technology to the pulmonary administration of insulin mist as a therapeutic measure for diabetes. METHODS: Insulin ejected from the ink-jet device was initially characterized by high-performance liquid chromatography (HPLC) and mass spectrometry. Its effects on D-glucose uptake rate by L6 cells were then investigated. Next, different insulin solutions (with or without additives or ink-jet processing) were subcutaneously administered, and their pharmacodynamic features were evaluated. Finally, decreases in plasma glucose level in rats were examined after ventilator-assisted pulmonary administration of insulin mist. RESULTS: Neither the HPLC nor the mass spectrometry profile of insulin was altered by the ink-jet process. The D-glucose uptake rate by L6 cells that received the recovered aerosolized insulin solution was similar to that of cells treated with control insulin, at 107%. Neither the addition of additives nor the ink-jet process used for insulin aerosolization impaired the plasma glucose-lowering action of subcutaneously injected insulin. Similarly, the efficacy of pulmonary insulin administration was not affected by the additives or the ink-jet process. Plasma glucose levels showed a trend towards decreasing after ventilator-assisted pulmonary administration of insulin mist. Plasma insulin level increased 30 min after the inhalation. CONCLUSIONS: The ink-jet process did not affect the quality or biological activity of insulin, suggesting the potential use of the ink-jet device for insulin inhalation therapy for diabetes.
Asunto(s)
Hipoglucemiantes/administración & dosificación , Insulina/administración & dosificación , Nebulizadores y Vaporizadores , Tecnología Farmacéutica , Absorción , Administración por Inhalación , Aerosoles , Animales , Arginina/química , Transporte Biológico/efectos de los fármacos , Glucemia/análisis , Línea Celular , Cresoles/química , Estabilidad de Medicamentos , Fluoresceína-5-Isotiocianato/administración & dosificación , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/farmacocinética , Hipoglucemiantes/química , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Insulina/análogos & derivados , Insulina/química , Insulina/farmacocinética , Insulina/farmacología , Cinética , Pulmón/citología , Pulmón/metabolismo , Masculino , Vehículos Farmacéuticos/química , Ratas , Ratas Wistar , Sarcosina/análogos & derivados , Sarcosina/químicaRESUMEN
Combination therapy with an α-glucosidase inhibitor and insulin is commonly performed for type 2 diabetes mellitus. We conducted a placebo-controlled double-blind comparative study to investigate the efficacy of combination therapy with miglitol and insulin. The patients with T2DM on insulin therapy were randomly assigned to either a miglitol treatment group (Group M) or a placebo group (Group P) and treated for 12 weeks. Meal tolerance tests were conducted at the observation period, week 0 and week 12 of the treatment period. Mean values of decrease in 1-h- and 2-h postprandial plasma glucose level were significantly larger in Group M than in Group P (60.3 ± 70.1 mg/dl vs. -5.1 ± 68.2 mg/dl (P < 0.001)), as was HbA1c as well (0.36 ± 0.66% vs. -0.03 ± 0.56% (P < 0.001)). Adverse events included abdominal distension and flatulence, which were significantly more frequent in Group M. The frequency of nocturnal hypoglycemia events tended to be reduced in Group M. Combined use of insulin and miglitol is useful for postprandial glucose regulation and improves glycemic control.
Asunto(s)
1-Desoxinojirimicina/análogos & derivados , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , 1-Desoxinojirimicina/administración & dosificación , 1-Desoxinojirimicina/efectos adversos , Anciano , Glucemia/análisis , Diabetes Mellitus Tipo 2/sangre , Método Doble Ciego , Quimioterapia Combinada , Femenino , Hemoglobina Glucada/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Placebos , Periodo PosprandialRESUMEN
A 59-year-old woman was diagnosed as having Graves' disease and type 1 diabetes. DNA molecular HLA typing detected DRB1(*)0405 and DQB1(*)0401, as well as the haplotypes of DRB1(*)0901-DQB1(*)0303. We also performed polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to identify allele variations of other loci. The patient's son also manifested Graves' disease and type 1 diabetes, with both cases having strikingly homologous clinical features. Familial clustering of Graves' disease and type 1 diabetes, and their tendency to occur together along with a similar clinical course suggest that their etiology may involve shared genetic factors.
Asunto(s)
Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 1/genética , Enfermedad de Graves/complicaciones , Enfermedad de Graves/genética , Adulto , Diabetes Mellitus Tipo 1/diagnóstico , Femenino , Enfermedad de Graves/diagnóstico , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: The large clinical trials proved that Basal-Bolus (BB) insulin therapy was effective in the prevention of diabetic complications and their progression. However, BB therapy needs multiple insulin injections per a day. In this regard, a biphasic insulin analogue needs only twice-daily injections, and is able to correct postprandial hyperglycemia. Therefore it may achieve the blood glucose control as same as that of BB therapy and prevent the diabetic complications including macroangiopathy. METHODS: In PROBE (Prospective, Randomized, Open, Blinded-Endpoint) design, forty-two type 2 diabetic patients (male: 73.8%, median(inter quartile range) age: 64.5(56.8-71.0)years) with secondary failure of sulfonylurea (SU) were randomly assigned to BB therapy with a thrice-daily insulin aspart and once-daily basal insulin (BB group) or to conventional therapy with a twice-daily biphasic insulin analogue (30 Mix group), and were followed up for 6 months to compare changes in HbA1c, daily glycemic profile, intima-media thickness (IMT) of carotid artery, adiponectin levels, amounts of insulin used, and QOL between the two groups. RESULTS: After 6 months, HbA1c was significantly reduced in both groups compared to baseline (30 Mix; 9.3(8.1-11.3) --> 7.4(6.9-8.7)%, p < 0.01, vs BB;8.9(7.7-10.0) --> 6.9(6.2-7.3)%, p < 0.01), with no significant difference between the groups in percentage change in HbA1c (30 Mix; -14.7(-32.5- (-)7.5)% vs BB -17.8(-30.1- (-)11.1)%, p = 0.32). There was a significant decrease in daily glycemic profile at all points except dinner time in both groups compared to baseline. There was a significant increase in the amount of insulin used in the 30 Mix group after treatment compared to baseline (30 Mix;0.30(0.17-0.44) --> 0.39(0.31-0.42) IU/kg, p = 0.01). There was no significant difference in IMT, BMI, QOL or adiponectin levels in either group compared to baseline. CONCLUSION: Both BB and 30 mix group produced comparable reductions in HbA1c in type 2 diabetic patients with secondary failure. There was no significant change in IMT as an indicator of early atherosclerotic changes between the two groups. The basal-bolus insulin therapy may not be necessarily needed if the type 2 diabetic patients have become secondary failure. TRIAL REGISTRATION: Current Controlled Trials number, NCT00348231.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/administración & dosificación , Insulina/administración & dosificación , Compuestos de Sulfonilurea/administración & dosificación , Adiponectina/sangre , Adulto , Anciano , Aterosclerosis/patología , Glucemia/metabolismo , Progresión de la Enfermedad , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Hemoglobina Glucada/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Calidad de Vida , Método Simple Ciego , Resultado del Tratamiento , Túnica Íntima/patología , Túnica Media/patologíaRESUMEN
Maturity-onset diabetes of the young type 5 (MODY5) is caused by mutation of hepatocyte nuclear factor 1beta (HNF1 beta) (TCF2) gene, resulting in a wide range of phenotypes including diabetes and renal abnormalities, but little is known about the pathogenesis of the clinical spectrum. We describe a 27-year-old Japanese male with the MODY phenotype including an atrophic kidney and multiple renal cysts. Genetic analysis revealed the patient to be heterozygous for a nonsense mutation in codon 276 of the HNF1beta gene (CGA or Arginine to TGA or stop codon; R276X). To clarify the pathophysiological relevance of this mutation, we conducted an in vitro study monitoring human C-peptide secretion after transfecting both the HNF1beta mutant cDNA and preproinsulin cDNA into a murine beta cell line, MIN6. Functional studies of the transformed MIN6 cells indicated that expression of the R276X caused a significant decrease in glucose-stimulated insulin secretion but no change in either KCl-stimulated or basal insulin secretion. These results suggest that the R276X functions in a negative manner in regard to metabolic responses of insulin secretion in beta cells. Analysis with light and electron microscopy on biopsied kidney specimens suggested that the origin of the cysts might be glomeruli but the primary lesion could be tubules.
Asunto(s)
Codón sin Sentido , Diabetes Mellitus Tipo 2/genética , Factor Nuclear 1-beta del Hepatocito/genética , Adulto , Edad de Inicio , Arginina/genética , Péptido C/metabolismo , Células Cultivadas , Diabetes Mellitus Tipo 2/clasificación , Diabetes Mellitus Tipo 2/complicaciones , Humanos , Células Secretoras de Insulina/metabolismo , Masculino , Linaje , Enfermedades Renales Poliquísticas/complicaciones , Enfermedades Renales Poliquísticas/patología , TransfecciónRESUMEN
BACKGROUND: Although oxidative stress by accumulation of reactive oxygen species (ROS) in diabetes has become evident, it remains unclear what genes, involved in redox balance, would determine susceptibility for development of atherosclerosis in diabetes. This study evaluated the effect of genetic polymorphism of enzymes producing or responsible for reducing ROS on coronary artery calcification in type 2 diabetes (T2D). METHODS: An index for coronary-arteriosclerosis, coronary artery calcium score (CACS) was evaluated in 91 T2D patients using a multi-slice computed tomography. Patients were genotyped for ROS-scavenging enzymes, Glutathione peroxidase-1 (GPx-1), Catalase, Mn-SOD, Cu/Zn-SOD, as well as SNPs of NADPH oxidase as ROS-promoting elements, genes related to onset of T2D (CAPN10, ADRB3, PPAR gamma, FATP4). Age, blood pressure, BMI, HbA1c, lipid and duration of diabetes were evaluated for a multivariate regression analysis. RESULTS: CACS with Pro/Leu genotype of the GPx-1 gene was significantly higher than in those with Pro/Pro (744 +/- 1,291 vs. 245 +/- 399, respectively, p = 0.006). In addition, genotype frequency of Pro/Leu in those with CACS >or= 1000 was significantly higher than in those with CACS < 1000 (45.5% vs. 18.8%; OR = 3.61, CI = 0.97-13.42; p = 0.045) when tested for deviation from Hardy-Weinberg's equilibrium. Multivariate regression analyses revealed that CACS significantly correlated with GPx-1 genotypes and age. CONCLUSION: The presence of Pro197Leu substitution of the GPx-1 gene may play a crucial role in determining genetic susceptibility to coronary-arteriosclerosis in T2D. The mechanism may be associated with a decreased ability to scavenge ROS with the variant GPx-1.
Asunto(s)
Calcinosis/genética , Enfermedad Coronaria/genética , Diabetes Mellitus Tipo 2/genética , Angiopatías Diabéticas/genética , Glutatión Peroxidasa/genética , Sustitución de Aminoácidos , Calcinosis/diagnóstico por imagen , Calcinosis/enzimología , Estudios de Casos y Controles , Enfermedad Coronaria/diagnóstico por imagen , Enfermedad Coronaria/enzimología , Diabetes Mellitus Tipo 2/enzimología , Angiopatías Diabéticas/diagnóstico por imagen , Angiopatías Diabéticas/enzimología , Femenino , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Tomografía Computarizada por Rayos X , Glutatión Peroxidasa GPX1RESUMEN
The stereoselective alkenylation of unsaturated compounds by means of a (Z)-alkenyl sulfone-titanocene(II) system is described. Treatment of alkynes and (Z)-alkenyl methyl sulfones with the titanocene(II) reagent Cp2Ti[P(OEt)3]2 produced conjugated dienes. This alkenylation system is also applicable to polar C=O bonds; the simple mixing of carbonyl compounds, (Z)-alkenyl methyl sulfones, and the titanocene(II) reagent formed allylic alcohols. The advantages of alkenylation are that it requires no prepreparation of the alkenylmetal reagent and that it proceeds with complete stereoselectivity.
RESUMEN
Titanocene(II)-promoted cross coupling of alkynyl- and (Z)-alkenyl sulfones affords alpha-(phenylsulfonyl)alkenyltitanium species. Further treatment of these species with the titanocene(II) reagent generates titanium vinylvinylidene complexes, which react with carbonyl compounds in one pot to produce substituted vinylallenes with complete stereoselectivity. By using alpha,beta-unsaturated ketones, 1,3,4,6-tetraenes are also obtained stereoselectively.
RESUMEN
We have established insulin-secreting cell line, L1-INS/fur cells, by engineering 3T3-L1 murine preadipocytes with human preproinsulin cDNA. Analysis with HPLC, mass spectrometry and immunological assay identified human insulin in the culture medium. Notably, secretion of insulin from L1-INS/fur cell was increased 8.2 times higher after induction of cellular differentiation. The increment of insulin secretion during differentiation was further enhanced by additive treatment with thiazolidinedione, a promoting agent of adipocyte differentiation. This observation strongly suggests that the enhancement of insulin secretion is tightly associated with cellular differentiation process itself. Expression rate of the insulin transgene was not changed after the additional treatment with thiazolidinedione. On the other hand, furin gene expression by Northern analysis showed an increase, and Western analysis revealed even more reduction in cellular content of proinsulin. These results indicate that mechanism of the observed enhancement in insulin secretion during the differentiation is mainly due to increased capacity of the proinsulin processing by induction of furin. Results of our present study will provide important information on cell-based therapy using undifferentiated progenitors and tissue stem cells.
Asunto(s)
Adipocitos/trasplante , Diferenciación Celular/fisiología , Diabetes Mellitus Experimental/terapia , Proinsulina/metabolismo , Células 3T3-L1 , Adipocitos/fisiología , Animales , Diferenciación Celular/genética , Diabetes Mellitus Experimental/genética , Furina/genética , Furina/metabolismo , Expresión Génica , Humanos , Masculino , Ratones , Ratones Desnudos , Proinsulina/genética , Ingeniería de TejidosAsunto(s)
Aeronaves , Complicaciones de la Diabetes , Enfermedad de Graves/complicaciones , Embolia Pulmonar/etiología , Viaje , Trombosis de la Vena/etiología , Anciano , Anticoagulantes/uso terapéutico , Aspirina/uso terapéutico , Femenino , Humanos , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/terapia , Factores de Riesgo , Síndrome , Trombosis de la Vena/diagnóstico , Trombosis de la Vena/terapia , Warfarina/uso terapéuticoRESUMEN
Recently, islet transplantation in the treatment of type 1 diabetes has been revisited with improved results. This approach has the potential to restore the regulatory unit of endocrine pancreas, but it cannot be a definite solution because of its limitation for the use of toxic immune-suppressive agents and limited number of donors. One possible way to restore the insulin secretion safely is with cell therapy using tissue engineering of a patient's own somatic cells by transduction of the corresponding gene of interest, in which extrapancreatic cells are engineered to secrete insulin. We constructed a somatic cell therapy system using a furin-cleavable insulin gene and somatic cells of mesenchymal origin. We also tested a semipermeable chamber that can contain allo- or xenogeneic insulin-secreting cells and found that the device could be helpful for cell therapy. This novel approach should provide a feasible method for treatment of diabetes mellitus without the use of any toxic agent or of embryonic stem cells that involve ethical implications.
Asunto(s)
Diabetes Mellitus Tipo 1/terapia , Terapia Genética/métodos , Trasplante de Islotes Pancreáticos , Ingeniería de Tejidos/métodos , Técnicas de Transferencia de Gen , Terapia Genética/instrumentación , Humanos , Ingeniería de Tejidos/instrumentaciónRESUMEN
Common type 2 diabetes mellitus is a disorder that is though to develop by interaction between genetic and environmental factors. Among these factors, peroxisome proliferator-activated receptor (PPAR)gamma gene was identified as a genetic element which variant form, Pro12Ala, was shown to have differential metabolic activity than the wild type. To elucidate the mechanism of interaction between genetic and environmental factors in development of type 2 diabetes, we analyzed prevalence and metabolic status in the context of the variant form of PPARgamma in 105 native Japanese and 145 Japanese American, both should have different environmental factors. The observed frequency of Pro-allele in Japanese American with diabetes was significantly higher than those with normal glucose tolerance (NGT) (P=0.015), while that in native Japanese with diabetes was not different from those with NGT. Alternatively, Japanese Americans with diabetes with Pro/Pro genotype had significantly higher BMI (P=0.024) and higher fasting serum insulin (P=0.043) level than native Japanese, showing that individuals with Ala-allele could be more sensitive to insulin than those with Pro/Pro genotype. The data with emigrants suggests the possible interaction of gene-environment in the development of type 2 diabetes.
Asunto(s)
Diabetes Mellitus Tipo 2/genética , Variación Genética , Receptores Citoplasmáticos y Nucleares/genética , Factores de Transcripción/genética , Anciano , Pueblo Asiatico , Secuencia de Bases , Cartilla de ADN , Diabetes Mellitus Tipo 2/epidemiología , Frecuencia de los Genes , Intolerancia a la Glucosa/epidemiología , Intolerancia a la Glucosa/genética , Humanos , Japón/epidemiología , Japón/etnología , Estados UnidosRESUMEN
We investigated the relationship between peroxisome proliferator-activated receptor gamma (PPARgamma) Pro12Ala substitution and insulin resistance in subjects with normal insulin secretory capacity, since it has been reported that PPARgamma may affect not only insulin resistance but also insulin secretion. We examined 81 Japanese male patients with untreated essential hypertension using the glucose clamp technique. We found 77 subjects with Pro/Pro and 4 subjects with Pro/Ala genotype, and the glucose disposal rate was not significantly different between the two groups. Fasting plasma glucose, fasting immunoreactive insulin, total cholesterol, HDL cholesterol, and triglyceride were not significantly different between the two groups. There were also no significant differences between groups in homeostasis model assessment of insulin resistance (HOMA-R) values, area under the curve (AUC) for plasma glucose, or AUC for IRI in 75 g OGTT. Because insulin sensitivity is likely to be determined by polygenic factors, we also investigated beta3 adrenergic receptor Trp64Arg polymorphism as a possible determinant of insulin resistance. In conclusion, no significant association was observed between PPARgamma2 substitution and insulin sensitivity in the present cohort of Japanese hypertensive patients.